gentamicin has been researched along with Gonorrhea in 69 studies
Gentamicins: A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS.
Gonorrhea: Acute infectious disease characterized by primary invasion of the urogenital tract. The etiologic agent, NEISSERIA GONORRHOEAE, was isolated by Neisser in 1879.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Patients aged 15-60 years diagnosed with uncomplicated urogenital gonorrhea were randomly assigned to either gentamicin 240 mg intramuscularly plus azithromycin 2 g orally, or gemifloxacin 320 mg orally plus azithromycin 2 g orally." | 9.19 | The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. ( Ghanem, KG; Hook, EW; Johnson, S; Kerndt, PR; Kirkcaldy, RD; Moore, PC; Papp, JR; Philip, SS; Weinstock, HS; Wiesenfeld, HC, 2014) |
| "The use of single-dose cefixime, ceftriaxone, and gentamicin-based regimens for treatment of gonorrhea appears to be safe and acceptable for use in practice." | 9.12 | Safety of Single-Dose Oral Cefixime, Intramuscular Ceftriaxone, or Intramuscular Gentamicin for the Treatment of Gonorrhea: A Systematic Review and Meta-analysis. ( Dresser, J; Wilby, KJ, 2021) |
| "Gentamicin-based regimens should be reserved for second-line treatment of urogenital and extragenital gonorrhea infections." | 9.05 | The Use of Gentamicin for Treatment of Urogenital and Extragenital Gonorrhea: A Systematic Review of Efficacy Data. ( Burmeister, P; Smith, AJ; Su, S; Wilby, KJ, 2020) |
| "Gentamicin has been used for the treatment of gonorrhea in Malawi since 1993." | 8.12 | Gentamicin Susceptibility in Neisseria gonorrhoeae and Treatment Outcomes for Urogenital Gonorrhea After 25 Years of Sustained Gentamicin Use in Malawi. ( Bonongwe, N; Chen, JS; Chikaonda, T; Cohen, MS; Golparian, D; Hobbs, MM; Hoffman, IF; Jere, E; Kamtambe, B; Krysiak, R; Massa, C; Mathiya, E; Matoga, M; Ndalama, B; Unemo, M, 2022) |
| " Patients aged 15-60 years diagnosed with uncomplicated urogenital gonorrhea were randomly assigned to either gentamicin 240 mg intramuscularly plus azithromycin 2 g orally, or gemifloxacin 320 mg orally plus azithromycin 2 g orally." | 5.19 | The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. ( Ghanem, KG; Hook, EW; Johnson, S; Kerndt, PR; Kirkcaldy, RD; Moore, PC; Papp, JR; Philip, SS; Weinstock, HS; Wiesenfeld, HC, 2014) |
| "The use of single-dose cefixime, ceftriaxone, and gentamicin-based regimens for treatment of gonorrhea appears to be safe and acceptable for use in practice." | 5.12 | Safety of Single-Dose Oral Cefixime, Intramuscular Ceftriaxone, or Intramuscular Gentamicin for the Treatment of Gonorrhea: A Systematic Review and Meta-analysis. ( Dresser, J; Wilby, KJ, 2021) |
| "The efficacy and safety of piperacillin were compared with those of clindamycin plus gentamicin in 74 women with obstetric or gynecologic infections (such as endometritis, salpingitis and septic abortion)." | 5.06 | A comparison of piperacillin and clindamycin plus gentamicin in women with pelvic infections. ( Gunning, JE, 1986) |
| "Gentamicin-based regimens should be reserved for second-line treatment of urogenital and extragenital gonorrhea infections." | 5.05 | The Use of Gentamicin for Treatment of Urogenital and Extragenital Gonorrhea: A Systematic Review of Efficacy Data. ( Burmeister, P; Smith, AJ; Su, S; Wilby, KJ, 2020) |
| "Gentamicin has been used for the treatment of gonorrhea in Malawi since 1993." | 4.12 | Gentamicin Susceptibility in Neisseria gonorrhoeae and Treatment Outcomes for Urogenital Gonorrhea After 25 Years of Sustained Gentamicin Use in Malawi. ( Bonongwe, N; Chen, JS; Chikaonda, T; Cohen, MS; Golparian, D; Hobbs, MM; Hoffman, IF; Jere, E; Kamtambe, B; Krysiak, R; Massa, C; Mathiya, E; Matoga, M; Ndalama, B; Unemo, M, 2022) |
| "Centers for Disease Control and Prevention (CDC) guidelines recommend 240 mg gentamicin plus 2 g azithromycin for the treatment of gonorrhea in cephalosporin-allergic patients." | 3.96 | Gentamicin Alone Is Inadequate to Eradicate Neisseria Gonorrhoeae From the Pharynx. ( Barbee, LA; Bass, T; Golden, MR; Hughes, JP; Leclair, A; Morgan, J; Soge, OO; Werth, BJ, 2020) |
| " Based on clinical efficacy and cost, gentamicin 240 mg intramuscularly, and doxycycline 100 mg twice daily x 7 days was selected as the first line regimen to treat urethritis." | 3.76 | Neisseria gonorrhoeae antimicrobial susceptibility in Lilongwe, Malawi, 2007. ( Banda, B; Brown, LB; Cohen, MS; Hobbs, M; Hoffman, IF; Hoffman, M; Hosseinipour, MC; Kamanga, G; Kamwendo, D; Kanyamula, H; Krysiak, R; Mapanje, C; Martinson, F; Mhango, C, 2010) |
| "Susceptibility of Neisseria gonorrhoeae to gentamicin, the primary treatment for gonorrhea in Malawi since 1993, was determined by using agar dilution MICs, E-test MICs, disc diffusion, and clinical cure rate." | 3.69 | Development of an antimicrobial susceptibility surveillance system for Neisseria gonorrhoeae in Malawi: comparison of methods. ( Cohen, MS; Daly, CC; Davis, R; Hobbs, M; Hoffman, I; Maida, M; Mughogho, G; Zimba, D, 1997) |
| "Men with urethritis due to Neisseria gonorrhoeae were treated with gentamicin, which is inactive against Chlamydia." | 3.65 | Infection with Chlamydia group A in men with urethritis due to Neisseria gonorrhoeae. ( Nicol, CS; Oriel, JD; Reeve, P; Thomas, BJ, 1975) |
| "The fosfomycin group was terminated early after interim analysis revealed less than 60% efficacy." | 3.11 | Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial. ( Boyd, A; de Korne-Elenbaas, J; de Laat, M; de Vries, HJC; Heijman, T; Jongen, VW; Schim van der Loeff, MF; van Dam, AP; Wind, CM, 2022) |
| "Gentamicin is a potential alternative treatment requiring further evaluation." | 2.90 | Gentamicin as an alternative to ceftriaxone in the treatment of gonorrhoea: the G-TOG non-inferiority RCT. ( Brittain, C; Cole, M; Dewsnap, C; Duley, L; Harding, J; Hepburn, T; Jackson, L; Lawrence, T; Meakin, G; Montgomery, AA; Roberts, T; Ross, JD; Sprange, K; Tan, W; Thandi, S; White, J; Wilson, J, 2019) |
| "If undetected and untreated, gonorrhea and chlamydia can lead to infertility, ectopic pregnancy, and chronic pelvic pain and can facilitate HIV acquisition and transmission." | 2.72 | Chlamydia and Gonorrhea. ( Dombrowski, JC, 2021) |
| "For gentamicin, there was 86." | 1.72 | Spectinomycin, gentamicin, and routine disc diffusion testing: An alternative for the treatment and monitoring of multidrug-resistant Neisseria gonorrhoeae? ( Barazzetti, FH; Bazzo, ML; de Albuquerque, VCB; de Melo Machado, H; Golfetto, L; Martins, JM; Santos, TMD; Scheffer, MC; Schörner, MA, 2022) |
| "No gentamicin resistance was detected in clinical isolates, 2015-2020, hence this is likely to be an available treatment option for resistant gonococcal infections in NSW." | 1.62 | Is gentamicin a viable therapeutic option for treating resistant Neisseria gonorrhoeae in New South Wales? ( Armstrong, BH; Driscoll, T; El Nasser, J; Hogan, T; Kundu, R; Lahra, MM; Lewis, DA; Limnios, A; Ray, S; Shoushtari, M, 2021) |
| " Gentamicin, an old and inexpensive antibiotic, is recommended in combination with azithromycin for treatment failures cases with the first-line regimen as per the latest Centers for Disease Control and Prevention sexually transmitted disease treatment guidelines." | 1.48 | In Vitro Synergy Testing of Gentamicin, an Old Drug Suggested as Future Treatment Option for Gonorrhoea, in Combination With Six Other Antimicrobials Against Multidrug-Resistant Neisseria gonorrhoeae Strains. ( Bala, M; Bhargava, A; Bhatnagar, R; Kakran, M; Singh, V, 2018) |
| "Cefixime resistance was detected in 2." | 1.48 | Stably high azithromycin resistance and decreasing ceftriaxone susceptibility in Neisseria gonorrhoeae in 25 European countries, 2016. ( Amato-Gauci, AJ; Cole, MJ; Day, MJ; Jacobsson, S; Spiteri, G; Unemo, M; Woodford, N, 2018) |
| " An in vitro assessment of azithromycin in combination with gentamicin demonstrated inhibition of growth and suggests that clinical trials may be warranted to assess the utility of this combination in treating gonorrhea infections." | 1.42 | In vitro assessment of dual drug combinations to inhibit growth of Neisseria gonorrhoeae. ( Papp, JR; Pettus, K; Sharpe, S, 2015) |
| "Treatment with ampicillin, gentamicin, and clindamycin eliminated the infection, although uterine and adnexal tenderness persisted at the 6-week follow-up." | 1.28 | Gonococcal peritonitis after tubal ligation. A case report. ( Entman, SS; Weeks, AG, 1991) |
| "Gentamicin is a valuable alternative in the treatment of infections due to PPNG strains." | 1.26 | Gentamicin in the treatment of infections due to penicillinase-producing gonococci. ( Pang, R; Rajan, VS; Sng, EH; Tan, NJ, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 27 (39.13) | 18.7374 |
| 1990's | 4 (5.80) | 18.2507 |
| 2000's | 1 (1.45) | 29.6817 |
| 2010's | 20 (28.99) | 24.3611 |
| 2020's | 17 (24.64) | 2.80 |
| Authors | Studies |
|---|---|
| Dombrowski, JC | 1 |
| Matoga, M | 2 |
| Chen, JS | 1 |
| Krysiak, R | 2 |
| Ndalama, B | 1 |
| Massa, C | 1 |
| Bonongwe, N | 1 |
| Mathiya, E | 1 |
| Kamtambe, B | 1 |
| Jere, E | 1 |
| Chikaonda, T | 1 |
| Golparian, D | 3 |
| Unemo, M | 7 |
| Cohen, MS | 3 |
| Hobbs, MM | 1 |
| Hoffman, IF | 3 |
| de Vries, HJC | 1 |
| de Laat, M | 1 |
| Jongen, VW | 1 |
| Heijman, T | 1 |
| Wind, CM | 1 |
| Boyd, A | 1 |
| de Korne-Elenbaas, J | 1 |
| van Dam, AP | 1 |
| Schim van der Loeff, MF | 1 |
| Holley, CL | 2 |
| Dhulipala, V | 1 |
| Balthazar, JT | 1 |
| Le Van, A | 1 |
| Begum, AA | 1 |
| Chen, SC | 1 |
| Read, TD | 1 |
| Jerse, AE | 1 |
| Shafer, WM | 2 |
| Martins, JM | 1 |
| Scheffer, MC | 1 |
| de Melo Machado, H | 1 |
| Schörner, MA | 1 |
| Golfetto, L | 1 |
| Santos, TMD | 1 |
| Barazzetti, FH | 1 |
| de Albuquerque, VCB | 1 |
| Bazzo, ML | 1 |
| Jacobsson, S | 2 |
| Ayinde, O | 1 |
| Ross, JDC | 3 |
| Jackson, L | 3 |
| Rob, F | 2 |
| Klubalová, B | 1 |
| Nyčová, E | 1 |
| Hercogová, J | 1 |
| Cole, MJ | 4 |
| Tan, W | 4 |
| Fifer, H | 1 |
| Brittain, C | 4 |
| Duley, L | 5 |
| Hepburn, T | 4 |
| Lawrence, T | 3 |
| Montgomery, AA | 4 |
| Sprange, K | 3 |
| Thandi, S | 3 |
| Churchward, C | 1 |
| Tripodo, F | 1 |
| Woodford, N | 2 |
| Barbee, LA | 1 |
| Soge, OO | 1 |
| Morgan, J | 1 |
| Leclair, A | 1 |
| Bass, T | 1 |
| Werth, BJ | 1 |
| Hughes, JP | 1 |
| Golden, MR | 1 |
| Sfeir, MM | 1 |
| Burmeister, P | 1 |
| Su, S | 1 |
| Smith, AJ | 1 |
| Wilby, KJ | 2 |
| Mensforth, S | 1 |
| Ayinde, OC | 1 |
| Ross, J | 1 |
| Dresser, J | 1 |
| Armstrong, BH | 1 |
| Limnios, A | 1 |
| Lewis, DA | 2 |
| Hogan, T | 1 |
| Kundu, R | 1 |
| Ray, S | 1 |
| Shoushtari, M | 1 |
| El Nasser, J | 1 |
| Driscoll, T | 1 |
| Lahra, MM | 1 |
| Allen, GP | 1 |
| Deao, KM | 1 |
| Hill, SA | 1 |
| Schipelliti, SM | 1 |
| Tran, T | 1 |
| Singh, V | 2 |
| Bala, M | 2 |
| Bhargava, A | 2 |
| Kakran, M | 2 |
| Bhatnagar, R | 2 |
| Mann, LM | 1 |
| Kirkcaldy, RD | 4 |
| Papp, JR | 3 |
| Torrone, EA | 1 |
| Lu, P | 1 |
| Wang, S | 1 |
| Lu, Y | 1 |
| Neculai, D | 1 |
| Sun, Q | 1 |
| van der Veen, S | 1 |
| Day, MJ | 1 |
| Spiteri, G | 1 |
| Amato-Gauci, AJ | 1 |
| Sood, S | 1 |
| Agarwal, SK | 1 |
| Singh, R | 1 |
| Gupta, S | 1 |
| Sharma, VK | 1 |
| Cole, M | 2 |
| Dewsnap, C | 2 |
| Harding, J | 3 |
| Keogh, M | 1 |
| Roberts, TE | 1 |
| White, J | 2 |
| Wilson, J | 2 |
| Workowski, KA | 1 |
| Ross, JD | 4 |
| Meakin, G | 2 |
| Roberts, T | 1 |
| Oumeiri, BE | 1 |
| Eynden, FV | 1 |
| Stefanidis, C | 1 |
| Antoine, M | 1 |
| Nooten, GV | 1 |
| Weinstock, HS | 1 |
| Moore, PC | 1 |
| Philip, SS | 1 |
| Wiesenfeld, HC | 1 |
| Kerndt, PR | 1 |
| Johnson, S | 1 |
| Ghanem, KG | 1 |
| Hook, EW | 1 |
| Hathorn, E | 1 |
| Dhasmana, D | 1 |
| Pettus, K | 1 |
| Sharpe, S | 1 |
| Joshi, NC | 1 |
| Childs, M | 1 |
| Brown, LB | 1 |
| Kamanga, G | 2 |
| Mapanje, C | 1 |
| Kanyamula, H | 1 |
| Banda, B | 1 |
| Mhango, C | 2 |
| Hoffman, M | 1 |
| Kamwendo, D | 1 |
| Hobbs, M | 2 |
| Hosseinipour, MC | 1 |
| Martinson, F | 1 |
| Chisholm, SA | 1 |
| Quaye, N | 1 |
| Fredlund, H | 1 |
| Hoffmann, S | 1 |
| Jensen, JS | 1 |
| van de Laar, MJ | 1 |
| Ison, CA | 2 |
| Brown, L | 1 |
| Dowell, D | 1 |
| Pereira, R | 1 |
| Zabaneh, H | 1 |
| Bacos, M | 1 |
| Nassar, NT | 1 |
| Alami, SY | 1 |
| Kurban, AK | 1 |
| Main, C | 1 |
| Rajan, VS | 2 |
| Szarmach, H | 1 |
| Weuta, H | 1 |
| Wroński, A | 1 |
| Niezyporuk, W | 1 |
| Podziewski, J | 1 |
| Skarzyński, J | 1 |
| Thompson, SE | 1 |
| Hager, WD | 1 |
| Wong, KH | 1 |
| Lopez, B | 1 |
| Ramsey, C | 1 |
| Allen, SD | 1 |
| Stargel, MD | 1 |
| Thornsberry, C | 1 |
| Benigno, BB | 1 |
| Thompson, JD | 1 |
| Shulman, JA | 1 |
| Müller, G | 1 |
| Tan, NJ | 1 |
| Pang, R | 1 |
| Sng, EH | 1 |
| Risher, WH | 1 |
| McFadden, PM | 1 |
| Daly, CC | 1 |
| Hoffman, I | 1 |
| Maida, M | 1 |
| Zimba, D | 1 |
| Davis, R | 1 |
| Mughogho, G | 1 |
| Terho, P | 1 |
| Iskandar, IO | 1 |
| Naguib, F | 1 |
| El Gabry, K | 1 |
| Fanous, V | 1 |
| Biehler, H | 1 |
| Thelenberg, G | 1 |
| Crössmann, W | 1 |
| Danda, J | 1 |
| Dbalý, V | 1 |
| Hamáková, K | 1 |
| Klíma, J | 1 |
| Oriel, JD | 1 |
| Reeve, P | 1 |
| Thomas, BJ | 1 |
| Nicol, CS | 2 |
| Weeks, AG | 1 |
| Entman, SS | 1 |
| van Hall, MA | 1 |
| Petit, PL | 1 |
| van Hall, HN | 1 |
| Mouton, RP | 1 |
| Ndinya-Achola, JO | 1 |
| Gunning, JE | 1 |
| Bartunek, J | 1 |
| Kraft, D | 1 |
| Mayer-Hausner, E | 1 |
| Lawrence, AG | 1 |
| Phillips, I | 1 |
| Reeves, DS | 2 |
| Petzoldt, D | 1 |
| Hantschke, D | 3 |
| Strauss, P | 3 |
| Linzenmeier, G | 1 |
| Gahlen, D | 1 |
| Heller, W | 2 |
| Bowie, W | 1 |
| Ronald, AR | 1 |
| Krywulak, W | 1 |
| Cates, CY | 1 |
| Boutros, P | 1 |
| McCracken, GH | 1 |
| Eichenwald, HF | 1 |
| Hatschke, D | 1 |
| Jaeckel, A | 1 |
| Ruedy, J | 1 |
| Morrison, GD | 1 |
| Holzmann, H | 1 |
| Tupath-Barniske, R | 1 |
| Morsches, B | 1 |
| Meyer-Rohn, J | 1 |
| Mauss, J | 1 |
| Siboulet, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| New Antibiotic Treatment Options for Uncomplicated Anogenital Gonorrhoea Infections - a Double-blind Randomized Controlled Non-inferiority Trial[NCT03294395] | Phase 3 | 346 participants (Actual) | Interventional | 2017-09-18 | Completed | ||
| Gentamicin for Pharyngeal Gonorrhea - A Demonstration Study[NCT03632109] | Phase 2/Phase 3 | 13 participants (Actual) | Interventional | 2018-09-17 | Terminated (stopped due to Efficacy) | ||
| Randomized Clinical Trial Evaluating the Efficacy of Gentamicin/Azithromycin and Gemifloxacin/Azithromycin Combination Therapies as an Alternative Regimen for Uncomplicated Urogenital Gonorrhea[NCT00926796] | Phase 4 | 614 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Negative Pharyngeal Culture (NCT03632109)
Timeframe: 4-7 days (+/- 1 day) after treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Pharyngeal Gonorrhea | 2 |
laboratory defined MIC of infecting strain of N. gonorrhoeae at enrollment visit determined by agar dilution (NCT03632109)
Timeframe: baseline/enrollment visit
| Intervention | microgram/mL (Mean) |
|---|---|
| Single Arm | 6.9 |
serum gentamicin concentration (NCT03632109)
Timeframe: at 30, 45, or 60 minutes post dose
| Intervention | microgram/mL (Mean) |
|---|---|
| Single Arm | 21.2 |
Measured by a percent change in serum creatinine from baseline to test of cure (4-7 days following treatment) (NCT03632109)
Timeframe: 4-7 days (+/- 1 day) after treatment
| Intervention | percent change (Mean) |
|---|---|
| Single Arm | 5.2 |
Participant reported pain scale, with 1 being little to no pain, and 10 being the worst pain ever. (NCT03632109)
Timeframe: 4-7 days (+/- 1 day) after treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Single Arm | 2 |
Number of enrollees with positive pharyngeal culture at enrollment who have negative culture 10-17 days after treatment (NCT00926796)
Timeframe: 10-17 days after treatment.
| Intervention | participants (Number) |
|---|---|
| Regimen A: Gentamicin Plus Azithromycin | 10 |
| Regimen B: Gemifloxacin Plus Azithromycin | 15 |
Number of enrollees with positive rectal culture at enrollment who have negative culture 10-17 days after treatment (NCT00926796)
Timeframe: 10-17 days after treatment.
| Intervention | participants (Number) |
|---|---|
| Regimen A: Gentamicin Plus Azithromycin | 1 |
| Regimen B: Gemifloxacin Plus Azithromycin | 5 |
Percentage of enrollees negative by culture at cervix/urethra 10-17 days after treatment, regardless of history of re-exposure, among those with positive gonococcal cultures at enrollment (microbiological cure) (NCT00926796)
Timeframe: 10-17 days after treatment.
| Intervention | percentage of participants (Number) |
|---|---|
| Regimen B: Gemifloxacin Plus Azithromycin | 99.50 |
Percentage of enrollees negative by culture at cervix/urethra 10-17 days after treatment, regardless of history of re-exposure, among those with positive gonococcal cultures at enrollment (microbiological cure) (NCT00926796)
Timeframe: 10-17 days after treatment.
| Intervention | percentage of participants (Number) |
|---|---|
| Regimen A: Gentamicin Plus Azithromycin | 100 |
Number of treated participants experiencing mild, moderate, severe, or life-threatening adverse events (AEs) either temporarily associated or not associated with study product. (NCT00926796)
Timeframe: Day 0 through Day 30
| Intervention | participants (Number) |
|---|---|
| Regimen A: Gentamicin Plus Azithromycin | 157 |
| Regimen B: Gemifloxacin Plus Azithromycin | 185 |
Number of participants whose gonorrhea-related symptoms (e.g. vaginal/urethral discharge, dysuria, dyspareunia) present at enrollment has resolved by visit 2. (NCT00926796)
Timeframe: 10-17 days after treatment.
| Intervention | participants (Number) |
|---|---|
| Regimen A: Gentamicin Plus Azithromycin | 179 |
| Regimen B: Gemifloxacin Plus Azithromycin | 177 |
Minimum inhibitory concentration (micrograms/milliliter) of pretreatment gonorrhea isolates collected from participants (NCT00926796)
Timeframe: Isolates obtained at enrollment (Day 0).
| Intervention | micrograms/milliliter (Median) | |||||||
|---|---|---|---|---|---|---|---|---|
| Azithromycin | Cefixime | Ceftriaxone | Ciprofloxacin | Gemifloxacin | Gentamicin | Penicillin | Tetracycline | |
| Baseline | 0.25 | 0.015 | 0.008 | 0.004 | 0.004 | 4 | 0.5 | 0.5 |
For treatment failures (i.e., participants with positive culture at cervix/urethra 10-17 days after treatment), the minimum inhibitory concentrations for various antimicrobial agents (Azithromycin, Cefixime, Ceftriaxone, Ciprofloxacin, Gemifloxacin, Gentamicin, Penicillin, Tetracycline). (NCT00926796)
Timeframe: Isolates obtained at enrollment (Day 0).
| Intervention | micrograms/milliliter (Median) | |||||||
|---|---|---|---|---|---|---|---|---|
| Azithromycin | Cefixime | Ceftriaxone | Ciprofloxacin | Gemifloxacin | Gentamicin | Penicillin | Tetracycline | |
| Regimen B: Gemifloxacin Plus Azithromycin | 0.25 | 0.015 | 0.004 | 0.002 | 0.004 | 4 | 0.5 | 0.25 |
For treatment failures (i.e., participants with positive culture at cervix/urethra 10-17 days after treatment), number participants with clinical symptoms (vaginal/urethral discharge, dysuria, dyspareunia) at 10-17 days. (NCT00926796)
Timeframe: 10-17 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Vaginal/urethral discharge | Dysuria | Dyspareunia | |
| Regimen B: Gemifloxacin Plus Azithromycin | 0 | 0 | 0 |
8 reviews available for gentamicin and Gonorrhea
| Article | Year |
|---|---|
Chlamydia and Gonorrhea.
Topics: Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Chlamydia Infections; Doxycycline; Female; Gentami | 2021 |
Economic evaluation of antimicrobial resistance in curable sexually transmitted infections; a systematic review and a case study.
Topics: Anti-Bacterial Agents; Ceftriaxone; Cost-Benefit Analysis; Drug Resistance, Bacterial; Gentamicins; | 2023 |
The Use of Gentamicin for Treatment of Urogenital and Extragenital Gonorrhea: A Systematic Review of Efficacy Data.
Topics: Anti-Bacterial Agents; Clinical Trials as Topic; Drug Resistance, Bacterial; Drug Therapy, Combinati | 2020 |
Safety of Single-Dose Oral Cefixime, Intramuscular Ceftriaxone, or Intramuscular Gentamicin for the Treatment of Gonorrhea: A Systematic Review and Meta-analysis.
Topics: Anti-Bacterial Agents; Cefixime; Ceftriaxone; Gentamicins; Gonorrhea; Humans; Injections, Intramuscu | 2021 |
The effectiveness of gentamicin in the treatment of Neisseria gonorrhoeae: a systematic review.
Topics: Anti-Bacterial Agents; Gentamicins; Gonorrhea; Humans; Injections, Intramuscular; Neisseria gonorrho | 2014 |
Effectiveness of gentamicin for gonorrhoea treatment: systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; Gentamicins; Gonorrhea; Humans; Treatment Outcome; United States | 2012 |
Antimicrobiol therapy: therapeutic recommendations and a review of newer drugs. Part I. Therapy of infectious conditions.
Topics: Adolescent; Ampicillin; Anti-Bacterial Agents; Arthritis, Infectious; Bacteroides Infections; Brain | 1974 |
[Newer antibiotics].
Topics: Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antifungal Agents; Antitubercular Agents; Cephal | 1971 |
12 trials available for gentamicin and Gonorrhea
| Article | Year |
|---|---|
Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial.
Topics: Adult; Anti-Bacterial Agents; Ceftriaxone; Ertapenem; Fosfomycin; Gentamicins; Gonorrhea; Humans; Ne | 2022 |
Gentamicin 240 mg plus azithromycin 2 g vs. ceftriaxone 500 mg plus azithromycin 2 g for treatment of rectal and pharyngeal gonorrhoea: a randomized controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Dos | 2020 |
Gentamicin, azithromycin and ceftriaxone in the treatment of gonorrhoea: the relationship between antibiotic MIC and clinical outcome.
Topics: Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Drug Resistance, Bacterial; Gentamicins; Gonorrhea | 2020 |
Spontaneous clearance of genital and extragenital
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Ceftriaxone; Drug Therapy, Combination; Female; Gent | 2020 |
Gentamicin compared with ceftriaxone for the treatment of gonorrhoea (G-ToG): a randomised non-inferiority trial.
Topics: Adolescent; Adult; Aged; Azithromycin; Ceftriaxone; Dose-Response Relationship, Drug; Drug Therapy, | 2019 |
Gentamicin as an alternative to ceftriaxone in the treatment of gonorrhoea: the G-TOG non-inferiority RCT.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Ceftriaxone; Cost-Benefit Analysis; Drug Resistance, | 2019 |
The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea.
Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Drug Therapy, Combinat | 2014 |
Gentamicin versus ceftriaxone for the treatment of gonorrhoea (G-TOG trial): study protocol for a randomised trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Cos | 2016 |
The microbiology and therapy of acute pelvic inflammatory disease in hospitalized patients.
Topics: Adolescent; Adult; Amoxicillin; Anaerobiosis; Anti-Bacterial Agents; Bacteria; Drug Therapy, Combina | 1980 |
[Gonorrhoea treated by gentamicin (author's treatment)].
Topics: Clinical Trials as Topic; Drug Evaluation; Gentamicins; Gonorrhea; Humans; Male | 1976 |
A comparison of piperacillin and clindamycin plus gentamicin in women with pelvic infections.
Topics: Abortion, Septic; Abscess; Adolescent; Adult; Bacterial Infections; Bacteroides Infections; Clindamy | 1986 |
Treatment of gonorrhoea with single injections of gentamicin.
Topics: Blood Urea Nitrogen; Clinical Trials as Topic; Creatinine; Epididymitis; Female; Gentamicins; Gonorr | 1973 |
49 other studies available for gentamicin and Gonorrhea
| Article | Year |
|---|---|
Gentamicin Susceptibility in Neisseria gonorrhoeae and Treatment Outcomes for Urogenital Gonorrhea After 25 Years of Sustained Gentamicin Use in Malawi.
Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Ciprofloxacin; Female; Gentamicins; Gono | 2022 |
A Single Amino Acid Substitution in Elongation Factor G Can Confer Low-Level Gentamicin Resistance in
Topics: Amino Acid Substitution; Animals; Anti-Bacterial Agents; Drug Resistance, Bacterial; Female; Gentami | 2022 |
Spectinomycin, gentamicin, and routine disc diffusion testing: An alternative for the treatment and monitoring of multidrug-resistant Neisseria gonorrhoeae?
Topics: Agar; Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Ciprofloxacin; Gentamicins; Gonorrhea; Human | 2022 |
High-level in vitro resistance to gentamicin acquired in a stepwise manner in Neisseria gonorrhoeae.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Gentamicins; Gonorrhea; Humans; Microbial Sensiti | 2023 |
Gentamicin Alone Is Inadequate to Eradicate Neisseria Gonorrhoeae From the Pharynx.
Topics: Anti-Bacterial Agents; Azithromycin; Gentamicins; Gonorrhea; Homosexuality, Male; Humans; Male; Micr | 2020 |
Re: 'Gentamicin 240 mg plus azithromycin 2 g vs. ceftriaxone 500 mg plus azithromycin 2 g for treatment of rectal and pharyngeal gonorrhoea' by Rob et al.
Topics: Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Gentamicins; Gonorrhea; Humans; Neisseria gonorrho | 2020 |
'Gentamicin 240 mg plus azithromycin 2 g vs. ceftriaxone 500 mg plus azithromycin 2 g for treatment of rectal and pharyngeal gonorrhoea' - Author's reply.
Topics: Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Gentamicins; Gonorrhea; Humans; Neisseria gonorrho | 2020 |
Is gentamicin a viable therapeutic option for treating resistant Neisseria gonorrhoeae in New South Wales?
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Female; Gentamicins; Gonorrhea; Humans; Male; Mic | 2021 |
In vitro evaluation of antimicrobial resistance selection in Neisseria gonorrhoeae.
Topics: Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Ciprofloxacin; Doxycycline; Drug Resistance, Multi | 2021 |
In Vitro Synergy Testing of Gentamicin, an Old Drug Suggested as Future Treatment Option for Gonorrhoea, in Combination With Six Other Antimicrobials Against Multidrug-Resistant Neisseria gonorrhoeae Strains.
Topics: Anti-Infective Agents; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combinati | 2018 |
Susceptibility of Neisseria gonorrhoeae to Gentamicin-Gonococcal Isolate Surveillance Project, 2015-2016.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Epidemiological Monitoring; Gentamicins; Gonorrhe | 2018 |
A Subpopulation of Intracellular Neisseria gonorrhoeae Escapes Autophagy-Mediated Killing Inside Epithelial Cells.
Topics: Autophagosomes; Autophagy; Epithelial Cells; Gentamicins; Gonorrhea; HeLa Cells; Host-Pathogen Inter | 2019 |
Stably high azithromycin resistance and decreasing ceftriaxone susceptibility in Neisseria gonorrhoeae in 25 European countries, 2016.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxo | 2018 |
In vitro assessment of gentamicin and azithromycin-based combination therapy against Neisseria gonorrhoeae isolates in India.
Topics: Anti-Bacterial Agents; Azithromycin; Disease Management; Drug Resistance, Multiple, Bacterial; Drug | 2019 |
Gentamicin as an alternative treatment for gonorrhoea.
Topics: Anti-Bacterial Agents; Ceftriaxone; Drug Therapy, Combination; Gentamicins; Gonorrhea; Humans | 2019 |
Gonococcal ascending aortic aneurysm with penetrating ulcer and bovine arch.
Topics: Administration, Intravenous; Aged; Aneurysm, Infected; Anti-Bacterial Agents; Aorta; Aorta, Thoracic | 2015 |
In vitro assessment of dual drug combinations to inhibit growth of Neisseria gonorrhoeae.
Topics: Anti-Bacterial Agents; Azithromycin; Drug Combinations; Drug Interactions; Drug Resistance, Bacteria | 2015 |
Gentamicin Susceptibility among a Sample of Multidrug-Resistant Neisseria gonorrhoeae Isolates in India.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Female; Gentamicins; Go | 2016 |
Neisseria gonorrhoeae antimicrobial susceptibility in Lilongwe, Malawi, 2007.
Topics: Anti-Bacterial Agents; Doxycycline; Gentamicins; Gonorrhea; Humans; Malawi; Male; Microbial Sensitiv | 2010 |
An evaluation of gentamicin susceptibility of Neisseria gonorrhoeae isolates in Europe.
Topics: Adolescent; Anti-Bacterial Agents; European Union; Gentamicins; Gonorrhea; Humans; Microbial Sensiti | 2011 |
Viewpoint: Gentamicin for treatment of gonococcal urethritis in Malawi.
Topics: Anti-Bacterial Agents; Gentamicins; Gonorrhea; Humans; Malawi; Microbial Sensitivity Tests; Neisseri | 2010 |
Cephalosporin resistant Neisseria gonorrhoeae: time to consider gentamicin?
Topics: Anti-Bacterial Agents; Cephalosporin Resistance; Drug Substitution; Gentamicins; Gonorrhea; Humans; | 2012 |
Combination therapy for gonorrhoea: in vitro synergy testing.
Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Drug Synergism; Gentamicins; Gonorrhea; | 2013 |
Gonorrhea in the male: some aspects of treatment in Lebanon.
Topics: Acute Disease; Adolescent; Adult; Ampicillin; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; | 1980 |
Treatment of septic arthritis.
Topics: Anti-Bacterial Agents; Arthritis, Infectious; Cefazolin; Cephalosporins; Gentamicins; Gonorrhea; Hum | 2007 |
The treatment of gonorrhoea--beta lactamase producers.
Topics: 4-Quinolones; Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactamases; Cephalosporins; Gentami | 1983 |
[Sisomicin in the treatment of gonorrhea].
Topics: Adolescent; Adult; Drug Evaluation; Female; Gentamicins; Gonorrhea; Humans; Male; Microbial Sensitiv | 1983 |
[In-vitro sensitivity of Neisseria gonorrhoeae against penicillin, ampicillin, oxytetracycline, streptomycin, gentamycin, and sulprim (author's transl)].
Topics: Ampicillin; Anti-Bacterial Agents; Female; Gentamicins; Gonorrhea; Humans; Male; Microbial Sensitivi | 1980 |
Gentamicin in the treatment of infections due to penicillinase-producing gonococci.
Topics: Female; Gentamicins; Gonorrhea; Humans; Male; Microbial Sensitivity Tests; Neisseria gonorrhoeae; Pe | 1980 |
Neisseria gonorrhoeae mycotic ascending aortic aneurysm.
Topics: Adult; Aneurysm, Infected; Aortic Aneurysm; Ceftriaxone; Combined Modality Therapy; Drug Therapy, Co | 1994 |
Development of an antimicrobial susceptibility surveillance system for Neisseria gonorrhoeae in Malawi: comparison of methods.
Topics: Anti-Bacterial Agents; Gentamicins; Gonorrhea; Humans; Malawi; Microbial Sensitivity Tests; Neisseri | 1997 |
Chlamydia trachomatis in gonococcal and postgonococcal urethritis.
Topics: Adult; Chlamydia Infections; Chlamydia trachomatis; Gentamicins; Gonorrhea; Humans; Male; Penicillin | 1978 |
A comparative study of gentamicin, co-trimoxazole and trimethoprim-sulphametrol in acute gonorrheal urethritis.
Topics: Drug Combinations; Gentamicins; Gonorrhea; Humans; Male; Sulfamethoxazole; Sulfanilamides; Trimethop | 1978 |
[Double infection of ulcus molle and gonorrhea].
Topics: Adult; Chancroid; Gentamicins; Gonorrhea; Humans; Male; Streptomycin; Thailand; Travel | 1978 |
Infection with Chlamydia group A in men with urethritis due to Neisseria gonorrhoeae.
Topics: Antibodies; Chlamydia; Chlamydia Infections; Complement Fixation Tests; Culture Techniques; Fluoresc | 1975 |
Gonococcal peritonitis after tubal ligation. A case report.
Topics: Adult; Ampicillin; Clindamycin; Diagnosis, Differential; Female; Gentamicins; Gonorrhea; Humans; Per | 1991 |
Prevalence of resistance of N. gonorrhoeae to penicillin and three other antibiotics in a rural area in Kenya.
Topics: Drug Resistance, Microbial; Female; Gentamicins; Gonorrhea; Humans; Kenya; Male; Penicillin Resistan | 1991 |
[Treatment of gonorrhea in women using a single gentamicin administration].
Topics: Adolescent; Adult; Child; Cochlea; Drug Evaluation; Drug Tolerance; Female; Gentamicins; Gonorrhea; | 1974 |
Gentamicin in sexually transmitted disease.
Topics: Female; Gentamicins; Gonorrhea; Humans; Male; Urethritis | 1974 |
Gonococcal urethritis treated with gentamicin.
Topics: Female; Gentamicins; Gonorrhea; Humans; Male; Urethritis | 1974 |
[One-time gentamicin therapy of gonorrhea. Its effect on Treponema pallidum].
Topics: Animals; Gentamicins; Gonorrhea; Humans; Male; Orchitis; Rabbits; Treponema pallidum | 1972 |
Gentamicin in the treatment of gonorrhoea in females.
Topics: Adolescent; Adult; Bacteriological Techniques; Cervix Uteri; Drug Resistance, Microbial; Female; Fol | 1974 |
[Single Sulmycin (gentamycin)-treatment in gonorrhea].
Topics: Female; Gentamicins; Germany, West; Gonorrhea; Humans; Injections; Male; Retrospective Studies | 1973 |
[Effect of short-term high gentamycin levels on inner ear function].
Topics: Adult; Animals; Audiometry; Ear, Inner; Gentamicins; Gonorrhea; Guinea Pigs; Hearing Tests; Humans; | 1973 |
Antibiotic treatment of septic arthritis.
Topics: Ampicillin; Anti-Bacterial Agents; Arthritis, Infectious; Cloxacillin; Gentamicins; Gonorrhea; Haemo | 1973 |
Gentamicin in the treatment of gonococcal urethritis. A microbiological, pharmacological, and clinical study.
Topics: Adolescent; Adult; Culture Media; Gentamicins; Gonorrhea; Humans; Injections, Intramuscular; Male; M | 1973 |
[Effect of gentamicin on the motility of Treponema pallidum].
Topics: Gentamicins; Gonorrhea; Humans; Penicillins; Syphilis; Treponema Immobilization Test; Treponema pall | 1969 |
[Treatment of gonorrhea with sulmycin].
Topics: Adult; Female; Gentamicins; Gonorrhea; Humans; Male; Neisseria gonorrhoeae; Penicillin Resistance | 1970 |
Results of the minute treatment of gonorrhoea in 26,339 cases.
Topics: Anti-Bacterial Agents; Erythromycin; Female; Gentamicins; Gonorrhea; Humans; Kanamycin; Leucomycins; | 1972 |